RITAZAREM trial long-term follow-up -RTX vs AZA after RTX-induced remission in ANCA #vasculitis -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 #ACR20 @RheumNow https://t.co/bW7IaMnVCG

• Extended Follow-Up of Patients Recruited to a Randomized, Controlled Trial of R…

Physicians must perceive the patient as a person rather than a carrier of a disease disease - Eric Cassell. Check out this book, and other insights from @LCalabreseDO on patient/provider discordance #empathy #cleclinicrheum @HealioRheum @RheumNow https://t.co/f5jnUS701X

#ACR20 @RheumNow https://t.co/0Kfe3Zforl

• https://twitter.com/drtinamahajan/status/1325844984470310913

@SSNaushon MTX remains backbone of therapy given low cost, safety profile, and long experience with it. Majority of pts do well on MTX and do not require TNFi @Rheumnow.

Interesting Swedish abstract 1997 at #ACR20. Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?

L06: Mavrilimumab in #GCA ⭐️Efficacy and safety of MAV maintaining sustained remission 26w new and relapsing/ref #GCA Flare risk ➡️ 62% risk ⬇️ of flare w/ MAV Sustained remission➡️ 33% ⬆️ in MAV No diff in new or relapsing/ref pts, No diff in AE #ACR20 #ACRambassador

Fantastic session about the 2020 guidelines for management of RA! Soon to be published. One major difference from 2015 guidelines ➡️ Conditional recommendation to choose a Biologic over Triple Therapy in MTX-inadequate responders (Discussion about patient preference is key!) https://t.co/s016piIN7Q

• https://twitter.com/UNMC_Rheum/status/1325840359411343362

SLR comparing the 4-dose ANCA #vasculitis (AAV) rituximab regimen (widely used in RCTs) to 2-dose #rheumatoidarthritis RTX regimen (common in clinical practice), to induce AAV remission, finds no difference in efficacy or safety. Abs#2048 #ACR20 @RheumNow https://t.co/WBaWN9d8vs

• Comparison of Two Rituximab Regimens for Induction of Remission in Antineutroph…

.@LCalabreseDO from @ClevelandClinic is discussing the science of #empathy in #rheumatology at #ACR20. How important is empathy in your doctor-patient relationship? https://t.co/xIdPWmc7UV

Results of the FAST trial presented at #ACR20 - Safety study required by the EMA - Febuxostat non-inferior to allopurinol for any outcomes - Long-term use of febuxostat is not associated with an increased risk of death Published in @TheLancet today https://t.co/EvJGPpDCR8

• DEFINE_ME

Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovascular events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat @rheumnow #ACR20 Abstr#L08 #ACRbest

A new (better) approach to #rheumatic disease treatment has to include wellness, lifestyle, and beyond. And this includes #empathy, says @LCalabreseDO at #ACR20. https://t.co/paE1Io6uvC

With Phase 2 of the Accelerating Medicines Partnership study of SLE underway, an #ACR20 session featured a panel that reviewed the methods being used to generate data & discussed some of the findings. Read the recap → https://t.co/hTnCdfBn10

• Panel discusses emerging molecular insights from AMP SLE Network - ACR Converge…

Just watched David Beck’s talk on somatic mutations in VEXAS. Genotyping to link phenotypically diverse disease. Such an exciting strategy to identify additional unknown diseases!!! #ACR https://t.co/gU9HEZyjRP

FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2

• https://meet.acrconvergence.org/meetings/bFG6BTawj43DP9SbX